TAKE Solutions Limited (TAKE.NS)
INR 8.0
(-0.37%)
INR 8.0
(-0.37%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 881.05 Million INR | -60.73% |
| 2022 | 2.24 Billion INR | -81.66% |
| 2021 | 12.23 Billion INR | -33.69% |
| 2020 | 18.44 Billion INR | -25.72% |
| 2019 | 24.83 Billion INR | 6.4% |
| 2018 | 23.33 Billion INR | 26.6% |
| 2017 | 18.43 Billion INR | 35.47% |
| 2016 | 13.6 Billion INR | 12.05% |
| 2015 | 12.14 Billion INR | 31.67% |
| 2014 | 9.22 Billion INR | 5.87% |
| 2013 | 8.71 Billion INR | 4.12% |
| 2012 | 8.36 Billion INR | 12.98% |
| 2011 | 7.4 Billion INR | 21.82% |
| 2010 | 6.07 Billion INR | 18.43% |
| 2009 | 5.13 Billion INR | -0.33% |
| 2008 | 5.15 Billion INR | 29.46% |
| 2007 | 3.97 Billion INR | 53.94% |
| 2006 | 2.58 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 2.13 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 881.05 Million INR | -60.73% |
| 2023 Q4 | 881.05 Million INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 3.05 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 2.24 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 2.24 Billion INR | -81.66% |
| 2021 Q2 | 18.57 Billion INR | 0.0% |
| 2021 Q4 | 12.23 Billion INR | 0.0% |
| 2021 FY | 12.23 Billion INR | -33.69% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 18.44 Billion INR | 0.0% |
| 2020 Q2 | 20.62 Billion INR | 0.0% |
| 2020 FY | 18.44 Billion INR | -25.72% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 25.54 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 24.83 Billion INR | 0.0% |
| 2019 FY | 24.83 Billion INR | 6.4% |
| 2018 Q2 | 21.28 Billion INR | 0.0% |
| 2018 FY | 23.33 Billion INR | 26.6% |
| 2018 Q4 | 23.33 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 15.42 Billion INR | 0.0% |
| 2017 FY | 18.43 Billion INR | 35.47% |
| 2017 Q4 | 18.43 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 13.6 Billion INR | 0.0% |
| 2016 Q2 | 13.18 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 13.6 Billion INR | 12.05% |
| 2015 FY | 12.14 Billion INR | 31.67% |
| 2015 Q4 | 12.14 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q2 | 9.85 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2014 Q2 | 8.89 Billion INR | 0.0% |
| 2014 FY | 9.22 Billion INR | 5.87% |
| 2014 Q4 | 9.22 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 8.71 Billion INR | 4.12% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 8.99 Billion INR | 0.0% |
| 2013 Q4 | 8.71 Billion INR | 0.0% |
| 2012 FY | 8.36 Billion INR | 12.98% |
| 2012 Q4 | 8.36 Billion INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 8.27 Billion INR | 0.0% |
| 2011 FY | 7.4 Billion INR | 21.82% |
| 2011 Q4 | 7.4 Billion INR | 0.0% |
| 2010 FY | 6.07 Billion INR | 18.43% |
| 2009 FY | 5.13 Billion INR | -0.33% |
| 2008 FY | 5.15 Billion INR | 29.46% |
| 2007 FY | 3.97 Billion INR | 53.94% |
| 2006 FY | 2.58 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Biocon Limited | 560.7 Billion INR | 99.843% |
| Blue Jet Healthcare Limited | 10.58 Billion INR | 91.679% |
| Concord Biotech Limited | 17 Billion INR | 94.82% |
| Dishman Carbogen Amcis Limited | 95.81 Billion INR | 99.08% |
| Jubilant Ingrevia Limited | 47.31 Billion INR | 98.138% |
| Lyka Labs Limited | 1.56 Billion INR | 43.783% |
| Panacea Biotec Limited | 12.4 Billion INR | 92.899% |
| Piramal Pharma Limited | 153.11 Billion INR | 99.425% |
| SMS Lifesciences India Limited | 3.9 Billion INR | 77.439% |
| Supriya Lifescience Limited | 9.21 Billion INR | 90.436% |
| Syngene International Limited | 61.51 Billion INR | 98.568% |
| Zota Health Care Limited | 2.28 Billion INR | 61.413% |